# Report on the Performance of Drug and Biologics Firms in Conducting Postmarketing Requirements and Commitments; Availability; Correction
**AGENCY:**
Food and Drug Administration, HHS.
**ACTION:**
Notice of availability; correction.
**SUMMARY:**
The Food and Drug Administration (FDA) is correcting a notice of availability that appeared in the *Federal Register* of August 4, 2011 (76 FR 47211). The Agency is required to report annually in the *Federal Register* on the status of postmarketing requirements and commitments required of, or agreed upon by, holders of approved drug and biological products. The August 4, 2011, notice is the Agency's report on the status of the studies and clinical trials that applicants have agreed to, or are required to, conduct. The document was published with an error. This document corrects that error.
**FOR FURTHER INFORMATION CONTACT:**
Joyce A. Strong, Office of Policy and Planning, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, rm. 3208, Silver Spring, MD 20993-0002, 301-796-9148.
**SUPPLEMENTARY INFORMATION:**
In FR Doc. 2011-19806, appearing on page 47211 in the *Federal Register* of August 4, 2011, the following correction is made:
On page 47214, table 1 is corrected to read as follows:
| | NDA/ANDA (% of Total PMR or % of total PMC) | BLA (% of Total PMR or % of total PMC) |
| --- | --- | --- |
| Number of open PMRs | 526 | 149. |
| On-schedule open PMRs (see table 2 of this document) | 477 (91%) | 131 (88%). |
| Off-schedule open PMRs (see table 3 of this document) | 49 (9%) | 18 (12%). |
| Number of open PMCs | 473 | 307. |
| On-schedule open PMCs (see table 4 of this document) | 399 (84%) | 236 (77%). |
| Off-schedule open PMCs (see table 5 of this document) | 74 (16%) | 71 (23%). |
Dated: August 17, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.